4//SEC Filing
Jordan Erica 4
Accession 0000950170-25-015356
CIK 0001479290other
Filed
Feb 5, 7:00 PM ET
Accepted
Feb 6, 3:57 PM ET
Size
7.3 KB
Accession
0000950170-25-015356
Insider Transaction Report
Form 4
Jordan Erica
Chief Commercial Officer
Transactions
- Disposition to Issuer
Common Stock
2025-02-06−107,942→ 0 total - Disposition from Tender
Common Stock
2025-02-04$3.65/sh−6,922$25,265→ 107,942 total
Footnotes (2)
- [F1]The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer.
- [F2]Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") award then outstanding and not vested was canceled and converted into the right to receive an amount in cash, without interest thereon and subject to applicable withholding taxes, equal to the product of the Per Share Price and the total number of Shares subject to such unvested RSU award as of immediately prior to the Effective Time (as defined in the Merger Agreement).
Documents
Issuer
Revance Therapeutics, Inc.
CIK 0001479290
Entity typeother
Related Parties
1- filerCIK 0002012846
Filing Metadata
- Form type
- 4
- Filed
- Feb 5, 7:00 PM ET
- Accepted
- Feb 6, 3:57 PM ET
- Size
- 7.3 KB